UBXN10

Across TCGA pan-cancer cohorts, UBXN10 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBXN10 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher UBXN10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBXN10 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

THCA, LUSC, and LIHC are the cancer types where UBXN10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.098	0.941	<.001	42	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	12	view →
LIHC	DFS	Median	All	0.084	0.555	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	1.000	0.866	.019	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

UBXN10–THCA (OS)

Open the THCA breakdown →